MA46619B1 - Anticorps anti-il-33 et leurs utilisations - Google Patents
Anticorps anti-il-33 et leurs utilisationsInfo
- Publication number
- MA46619B1 MA46619B1 MA46619A MA46619A MA46619B1 MA 46619 B1 MA46619 B1 MA 46619B1 MA 46619 A MA46619 A MA 46619A MA 46619 A MA46619 A MA 46619A MA 46619 B1 MA46619 B1 MA 46619B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- treatment
- bind
- agents
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des anticorps qui se lient et neutralisent l'il -33 humain, et des procédés d'utilisation de ceux-ci, lesdits anticorps étant utiles en tant qu'agents pour le traitement d'états associés à une maladie allergique, notamment le traitement de la dermatite atopique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414258P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/058020 WO2018081075A1 (fr) | 2016-10-28 | 2017-10-24 | Anticorps anti-il-33 et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46619B1 true MA46619B1 (fr) | 2021-09-30 |
Family
ID=60263117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46619A MA46619B1 (fr) | 2016-10-28 | 2017-10-24 | Anticorps anti-il-33 et leurs utilisations |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10501536B2 (fr) |
| EP (1) | EP3532499B1 (fr) |
| JP (1) | JP6830533B2 (fr) |
| KR (1) | KR102266144B1 (fr) |
| CN (1) | CN109863173B (fr) |
| AR (1) | AR109948A1 (fr) |
| AU (1) | AU2017351183B2 (fr) |
| BR (1) | BR112019005139A2 (fr) |
| CA (1) | CA3039232C (fr) |
| CL (1) | CL2019001043A1 (fr) |
| CO (1) | CO2019003047A2 (fr) |
| CR (1) | CR20190179A (fr) |
| CY (1) | CY1124360T1 (fr) |
| DK (1) | DK3532499T3 (fr) |
| EA (1) | EA201990778A1 (fr) |
| EC (1) | ECSP19029758A (fr) |
| ES (1) | ES2878037T3 (fr) |
| HR (1) | HRP20211221T1 (fr) |
| HU (1) | HUE055621T2 (fr) |
| IL (1) | IL265689B2 (fr) |
| JO (1) | JOP20190093A1 (fr) |
| LT (1) | LT3532499T (fr) |
| MA (1) | MA46619B1 (fr) |
| MD (1) | MD3532499T2 (fr) |
| MX (1) | MX394799B (fr) |
| PE (1) | PE20191045A1 (fr) |
| PH (1) | PH12019500929A1 (fr) |
| PL (1) | PL3532499T3 (fr) |
| PT (1) | PT3532499T (fr) |
| RS (1) | RS62120B1 (fr) |
| SI (1) | SI3532499T1 (fr) |
| SM (1) | SMT202100442T1 (fr) |
| TN (1) | TN2019000086A1 (fr) |
| TW (2) | TWI676680B (fr) |
| UA (1) | UA121293C2 (fr) |
| WO (1) | WO2018081075A1 (fr) |
| ZA (1) | ZA201901935B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| EP4045641A1 (fr) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Lignées cellulaires mammifères déficientes en lipase/estérase modifiées par recombinaison |
| KR20220092927A (ko) | 2019-11-04 | 2022-07-04 | 메디뮨 리미티드 | 신장 장애를 치료하기 위한 항 il-33 치료제 |
| JP7843701B2 (ja) | 2019-11-04 | 2026-04-10 | メディミューン リミテッド | Ｉｌ－３３アンタゴニストの使用方法 |
| CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
| EP4118114A1 (fr) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anticorps anti-interleukine-33 et leurs utilisations |
| JP2023516497A (ja) | 2020-03-13 | 2023-04-19 | メドイミューン・リミテッド | Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法 |
| CN115867575A (zh) | 2020-04-06 | 2023-03-28 | 免疫医疗有限公司 | 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征 |
| WO2021228760A1 (fr) | 2020-05-11 | 2021-11-18 | Medimmune Limited | Formulations d'anticorps anti-il-33 |
| CN111620948B (zh) * | 2020-06-10 | 2022-04-08 | 南京赛新生物科技有限公司 | 针对il-33的抗体 |
| CN113603775B (zh) * | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| TW202423973A (zh) | 2022-08-19 | 2024-06-16 | 英商梅迪繆思有限公司 | 選擇患者以用ｉｌ—３３軸拮抗劑進行治療之方法 |
| AU2024392535A1 (en) * | 2023-11-27 | 2026-06-04 | Glaxosmithkline Intellectual Property Development Limited | Il-33 binding antibodies |
| CN122341639A (zh) | 2023-12-07 | 2026-07-03 | 免疫医疗有限公司 | 治疗哮喘的方法 |
| TW202540173A (zh) | 2024-04-04 | 2025-10-16 | 英商梅迪繆思有限公司 | 治療及選擇對象之方法 |
| WO2025242618A1 (fr) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Traitement de la bronchiectasie |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
| JP2010527936A (ja) | 2007-05-18 | 2010-08-19 | メディミューン，エルエルシー | 炎症性疾患におけるｉｌ−３３ |
| EP2475388B1 (fr) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Utilisation d'antagonistes de l'il-33 à des fins de traitement des maladies fibrotiques |
| ES2549637T3 (es) * | 2011-02-23 | 2015-10-30 | F. Hoffmann-La Roche Ag | Anticuerpos contra IL33R humano y la utilización de los mismos |
| FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| HUE064292T2 (hu) | 2013-12-26 | 2024-03-28 | Mitsubishi Tanabe Pharma Corp | Humán anti-IL-33 semlegesítõ monoklonális antitest |
| SG11201605580RA (en) * | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| CA2946511C (fr) * | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions et methodes pour le traitement de troubles lies aux cytokines |
| JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック， インコーポレイテッド | 抗インターロイキン−３３抗体及びその使用 |
| MX387295B (es) | 2015-03-31 | 2025-03-18 | Medimmune Ltd | Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos. |
| AU2017208099A1 (en) | 2016-01-14 | 2018-08-09 | Anaptysbio, Inc. | Inhibition of allergic reaction using an IL-33 inhibitor |
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
-
2017
- 2017-06-16 JO JOP/2019/0093A patent/JOP20190093A1/ar unknown
- 2017-10-13 TW TW107143762A patent/TWI676680B/zh active
- 2017-10-13 TW TW106135006A patent/TWI647238B/zh active
- 2017-10-13 AR ARP170102863A patent/AR109948A1/es unknown
- 2017-10-24 PT PT177945938T patent/PT3532499T/pt unknown
- 2017-10-24 CR CR20190179A patent/CR20190179A/es unknown
- 2017-10-24 WO PCT/US2017/058020 patent/WO2018081075A1/fr not_active Ceased
- 2017-10-24 SI SI201730830T patent/SI3532499T1/sl unknown
- 2017-10-24 JP JP2019522272A patent/JP6830533B2/ja active Active
- 2017-10-24 ES ES17794593T patent/ES2878037T3/es active Active
- 2017-10-24 KR KR1020197012190A patent/KR102266144B1/ko active Active
- 2017-10-24 HR HRP20211221TT patent/HRP20211221T1/hr unknown
- 2017-10-24 RS RS20210875A patent/RS62120B1/sr unknown
- 2017-10-24 CN CN201780065572.XA patent/CN109863173B/zh active Active
- 2017-10-24 US US15/791,641 patent/US10501536B2/en active Active
- 2017-10-24 MA MA46619A patent/MA46619B1/fr unknown
- 2017-10-24 UA UAA201903400A patent/UA121293C2/uk unknown
- 2017-10-24 TN TNP/2019/000086A patent/TN2019000086A1/en unknown
- 2017-10-24 MD MDE20190980T patent/MD3532499T2/ro unknown
- 2017-10-24 LT LTEP17794593.8T patent/LT3532499T/lt unknown
- 2017-10-24 EA EA201990778A patent/EA201990778A1/ru unknown
- 2017-10-24 HU HUE17794593A patent/HUE055621T2/hu unknown
- 2017-10-24 EP EP17794593.8A patent/EP3532499B1/fr active Active
- 2017-10-24 AU AU2017351183A patent/AU2017351183B2/en active Active
- 2017-10-24 BR BR112019005139-2A patent/BR112019005139A2/pt active Search and Examination
- 2017-10-24 SM SM20210442T patent/SMT202100442T1/it unknown
- 2017-10-24 PL PL17794593T patent/PL3532499T3/pl unknown
- 2017-10-24 PE PE2019000838A patent/PE20191045A1/es unknown
- 2017-10-24 MX MX2019004863A patent/MX394799B/es unknown
- 2017-10-24 IL IL265689A patent/IL265689B2/en unknown
- 2017-10-24 CA CA3039232A patent/CA3039232C/fr active Active
- 2017-10-24 DK DK17794593.8T patent/DK3532499T3/da active
-
2019
- 2019-03-28 CO CONC2019/0003047A patent/CO2019003047A2/es unknown
- 2019-03-28 ZA ZA201901935A patent/ZA201901935B/en unknown
- 2019-04-16 CL CL2019001043A patent/CL2019001043A1/es unknown
- 2019-04-25 PH PH12019500929A patent/PH12019500929A1/en unknown
- 2019-04-26 EC ECSENADI201929758A patent/ECSP19029758A/es unknown
- 2019-10-25 US US16/663,561 patent/US10913793B2/en active Active
-
2021
- 2021-07-26 CY CY20211100672T patent/CY1124360T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42622B1 (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA49726B1 (fr) | Formulation d'anticorps anti-cgrp | |
| MA45235B1 (fr) | Anticorps anti-c5 et leurs utilisations | |
| EP3411504A4 (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| MA49727A (fr) | Anticorps et polypeptides dirigés contre cd127 | |
| JOP20190093A1 (ar) | أجسام مضادة لـ il-33 واستخداماتها | |
| MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
| JOP20200157B1 (ar) | أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22 | |
| TN2019000099A1 (fr) | Anticorps anti-lag-3 et compositions | |
| MA40513A (fr) | Conjugués médicament-anticorps anti-cdh6 | |
| MA43094A1 (fr) | Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation | |
| MA45029B1 (fr) | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer | |
| MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
| MA45125B1 (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EA201992546A1 (ru) | Средства на основе антител к cd33 | |
| MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
| MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EP3362479A4 (fr) | Agents de type anticorps spécifiques de l'antigène cd19 humain et leurs utilisations | |
| MA40035A (fr) | Molécules d'anticorps de pd-l1 et leurs utilisations | |
| MA39342B2 (fr) | Anticorps il -21 | |
| MA45999A (fr) | Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| MA49607B2 (fr) | ANTICORPS MONOCLONAL POUR IL-5Rα | |
| GEAP202215316A (en) | Antibody variants |